Life sciences company, Broughton, will be rebranding and expanding its services into the cannabis market.
Broughton is building on years of experience in the pharmaceutical and next-generation nicotine products space to offer its services to the cannabinoids industry.
The company offers fully integrated scientific and regulatory consultancy, combined with in-house laboratory services, and will now focus on accelerating life-enhancing products to market within strategic markets including pharmaceuticals, nicotine and cannabinoids.
CEO Dr Paul Moran, who founded Broughton Laboratories in 2006, commented: “The launch of the Broughton brand formalises our rapidly developing position as a full-service solutions provider to the life sciences sector. We will continue our commitment to investing further into global operations delivering scientific and regulatory consultancy combined with comprehensive product development and laboratory services.
“This next phase of our expansion is a natural evolution to grow capacity and capabilities into the broad life sciences sector as technologies improve to target unmet market needs.”
CSO, Chris Allen, commented: “One exciting aspect of this change is that it facilitates the expansion of our existing pharmaceutical quality and product stability services to support providers of pharmaceutical inhalation products.
“With expertise in device optimisation, human factor studies, navigating complex regulatory pathways for combination products and a track record of quality compliance, our broad expert team can support device development from concept to commercialisation.’’
Moran added: “The expanding team at Broughton hold extensive knowledge of their specialist fields. This rebrand brings together this expertise with a fresh focus on the journey of our clients’ products to meet an unmet market need. This is an exciting time for the business that will enable us to continue to innovate as we contribute to global health and wellbeing.”
[activecampaign form=31]
